Clinical Effects of Trithiozine,a Newer Gastric Anti-Secretory Agent

Abstract

Trithiozine is a new product which in animal studies proved to have a marked anti-secretory and anti-ulcer effect, along with a very low acute and chronic toxicity and no ganglioplegic, anticholinergic and anti-H₂ activity.

Clinical trials with trithiozine have been performed in some European countries. The results of these trials, most of which were conducted on a double-blind basis, and including already several hundreds of patients, have shown that oral trithiozine:

exerts a very significant action on both basal and stimulated gastric acid

secretion, without a rebound hypersecretion;

promotes, in most patients, a complete endoscopic healing of peptic ulcer,

in addition to an early symptomatic relief;

has a mild sedative action;

does not affect the pancreatic secretion;

is well tolerated even for long-term (up to 10 months) treatments.